Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Enasidenib mesylate by Bristol-Myers Squibb for Neuroblastoma: Likelihood of Approval
Enasidenib mesylate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Neuroblastoma. According to GlobalData, Phase...
Enasidenib mesylate by Bristol-Myers Squibb for Neuroendocrine Carcinoma: Likelihood of Approval
Enasidenib mesylate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Neuroendocrine Carcinoma. According to GlobalData,...
Enasidenib mesylate by Bristol-Myers Squibb for Chondrosarcoma: Likelihood of Approval
Enasidenib mesylate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase...
Enasidenib mesylate by Bristol-Myers Squibb for Cytopenia: Likelihood of Approval
Enasidenib mesylate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Cytopenia. According to GlobalData, Phase...